INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2005

Green tea extract shows minimal clinical activity in hormone refractory prostate cancer.

Nineteen patients with hormone refractory prostate cancer received 250 mg green tea extract capsules twice daily in a prospective clinical trial. Of the 15 participants who finished at least 2 months of treatment, 9 showed progressive disease within 2 months. The remaining 6 individuals developed disease progression after an additional 1 to 4 months of therapy, demonstrating minimal clinical efficacy.

Study type
Prospective clinical trial
Who was studied
19 patients with hormone refractory prostate cancer
What was measured
Prostate-specific antigen or measurable disease progression

THE PAPER

A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach.

Choan E, Segal R, Jonker D, Malone S, Reaume N, Eapen L, Gallant V. Urol Oncol, 2005.

PubMed 15869995 ↗DOI 10.1016/j.urolonc.2004.10.008 ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.